Kailera Therapeutics(KLRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KLRA Kailera Therapeutics

Closed Juneteenth National Independence Day 06-18 16:00:00 EDT

19.90

+0.77

+4.03%

盘后19.90

+0.000.00%

19:12 EDT

High20.49	Low19.21	Vol4.36M
Open19.38	D1 Closing19.13	Amplitude6.69%
Mkt Cap2.58B	Tradable Cap893.95M	Total Shares129.54M
T/O86.56M	T/O Rate9.70%	Tradable Shares44.92M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KLRA","market":"US","secType":"STK","nameCN":"Kailera Therapeutics","latestPrice":19.9,"timestamp":1781812800000,"preClose":19.13,"halted":0,"volume":4355889,"hourTrading":{"tag":"盘后","latestPrice":19.9,"preClose":19.9,"latestTime":"19:12 EDT","volume":1074217,"amount":21376856.5479,"timestamp":1781824372724,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.040250914793518014,"floatShares":44921899,"shares":129537300,"eps":-1.204378,"marketStatus":"Closed Juneteenth National Independence Day","change":0.77,"latestTime":"06-18 16:00:00 EDT","open":19.38,"high":20.49,"low":19.21,"amount":86561628.804258,"amplitude":0.066911,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.204378,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782115200000},"marketStatusCode":7,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":19.13,"preHourTrading":{"tag":"盘前","latestPrice":19.52,"preClose":19.13,"latestTime":"08:46 EDT","volume":16,"amount":306.47,"timestamp":1781786800127,"change":0.39,"changeRate":0.020387,"amplitude":0.020387},"postHourTrading":{"tag":"盘后","latestPrice":19.9,"preClose":19.9,"latestTime":"19:12 EDT","volume":1074217,"amount":21376856.5479,"timestamp":1781824372724,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":8.179265298061729},"requestUrl":"/m/hq/s/KLRA/tweets","defaultTab":"tweets","newsList":[{"id":"2641812390","title":"Kailera Therapeutics - Phase 2 Ribupatide Oral Shows up to 12.1% Mean Weight Loss at 26 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2641812390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641812390?lang=en_us&edition=fundamental","pubTime":"2026-06-06 07:37","pubTimestamp":1780702671,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nFWN42D0RY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641123920","title":"Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2641123920","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641123920?lang=en_us&edition=fundamental","pubTime":"2026-06-06 07:32","pubTimestamp":1780702320,"startTime":"0","endTime":"0","summary":"Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and ove","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/05/3307661/0/en/Hengrui-Pharma-and-Kailera-Therapeutics-Present-Ribupatide-Clinical-Data-at-ADA-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","PK","PD","AUC","LU1169589451.USD","BK4139","LU1169590202.USD","KLRA","BK4218","BK4181","BK4123"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639168796","title":"Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2639168796","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639168796?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:05","pubTimestamp":1779998700,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., May  28, 2026  (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3303260/0/en/Kailera-Therapeutics-to-Present-at-the-2026-Jefferies-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCSG","LU0029874061.USD","BK4585","LABU","BK4139","KLRA","BK4588","BK4581","XLV","BK4137","LU0128526141.USD","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639697868","title":"Jefferies Sticks to Their Buy Rating for Kailera Therapeutics, Inc. (KLRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2639697868","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639697868?lang=en_us&edition=fundamental","pubTime":"2026-05-28 23:55","pubTimestamp":1779983733,"startTime":"0","endTime":"0","summary":"Jefferies analyst Roger Song maintained a Buy rating on Kailera Therapeutics, Inc. today and set a price target of $48.00. Song covers the Healthca...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-their-buy-rating-for-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-their-buy-rating-for-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638673576","title":"TD Cowen Reaffirms Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638673576","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638673576?lang=en_us&edition=fundamental","pubTime":"2026-05-27 13:15","pubTimestamp":1779858913,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Yaron Werber maintained a Buy rating on Kailera Therapeutics, Inc. yesterday. The company’s shares closed yesterday at USD21.57. W...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-reaffirms-their-buy-rating-on-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-reaffirms-their-buy-rating-on-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COWN","KLRA","TD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638052823","title":"Kailera Therapeutics Q1 EPS $(3.65) Misses $(0.68) Estimate as R&D Spend Jumps to $70.9M","url":"https://stock-news.laohu8.com/highlight/detail?id=2638052823","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638052823?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:50","pubTimestamp":1779828607,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics (NASDAQ:KLRA) reported quarterly losses of $(3.65) per share which missed the analyst consensus estimate of $(0.68) by 444.78 percent as R&amp;D spend Jumps to $70.9M.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52795466/kailera-therapeutics-q1-eps-3-65-misses-0-68-estimate-as-r-d-spend-jumps-to-70-9m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kailera Therapeutics Q1 EPS $(3.65) Misses $(0.68) Estimate as R&D Spend Jumps to $70.9M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638540348","title":"Kailera Q1 FY26 net loss more than quadruples to $78.87 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2638540348","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638540348?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:02","pubTimestamp":1779825771,"startTime":"0","endTime":"0","summary":"Kailera posted a net loss of $78.87 million in Q1 2026, widening from a $17.98 million loss a year earlier.Research and development expenses more than doubled to $70.87 million, while general and administrative costs rose 33.88% to $13.79 million.Cash, cash equivalents and marketable securities totaled $581.9 million as of March 31, with IPO proceeds expected to fund operations into mid-2028.Advanced obesity pipeline with five late-stage global trials initiated, including the KaiNETIC Phase 3 program for once-weekly ribupatide injection.Reported new partner-led topline data in China for oral GLP-1 agonist KAI-7535 in type 2 diabetes and first-in-human Phase 1 results for injectable tri-agonist KAI-4729.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDLpWX5D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B1G9TM23.USD","LU2088747998.USD","SG9999010078.USD","BK4139","LU0886674414.USD","BK1601","BK4112","LU0224508324.USD","BK4588","BK1559","BK1216","IE00BGHQF748.EUR","80016","NDAQ","KLRA","SG9999014005.SGD","LU2088748020.USD","LU2088748293.HKD","LU2095319765.USD","LU0314104364.USD","LU1163227579.USD","00016","LU2226123490.SGD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","IE00B1G9TL16.USD","SG9999002463.SGD","SG9999014039.USD","LU2226123227.USD","LU1539696804.USD","IE00BKPKM429.USD","BK1521","LU0096374516.USD","SUHJY","LU0229494975.USD","03145","SG9999014013.SGD","LU2210150020.SGD","LU1560770973.SGD","BK4585","IE00B64PRP62.GBP","LU0315179316.USD","IE00BSPPW651.USD","SG9999010052.SGD","IE00BN0W2V16.EUR","LU1163227496.USD","LU2088747725.USD","SG9999009997.SGD","LU2088748376.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638540558","title":"Kailera Therapeutics Inc - Q1 Net Loss $78.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2638540558","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638540558?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:02","pubTimestamp":1779825720,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUA8JWMQX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638540510","title":"Kailera Therapeutics Inc - Reports Positive Topline Data From Phase 3 Hrs-7535 and Phase 1 Hrs-4729 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2638540510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638540510?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:02","pubTimestamp":1779825720,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUA8JWMQX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638154062","title":"Kailera Therapeutics Inc - Cash on Hand Expected to Fund Operations Into Mid-2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2638154062","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638154062?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:02","pubTimestamp":1779825720,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUA8JWMQX:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638540384","title":"Press Release: Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2638540384","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638540384?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:02","pubTimestamp":1779825720,"startTime":"0","endTime":"0","summary":"-- Important progress across four clinical-stage programs demonstrating. -- Initiated five late-stage global clinical trials in obesity, including. -- Reported positive topline clinical data from three trials conducted by. our partner Hengrui in China, including new topline data from Phase 3. trial of oral small molecule GLP-1 receptor agonist HRS-7535 . in type 2 diabetes, and first-in-human topline data from Phase 1 trial. -- Cash on hand, including IPO proceeds, is expected to fund operations into. Renaud, continued, \"These achievements, combined with our successful IPO, have positioned us with the capital and operational strength to continue advancing multiple programs in parallel. We are focused on maintaining this momentum and executing across our clinical programs as we work to deliver differentiated therapies for the treatment of obesity.\". living with obesity or overweight. Data is anticipated in 2028.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRA","BMI","BK4157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637353143","title":"Kailera Therapeutics, Inc. (KLRA) Receives a Buy from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2637353143","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637353143?lang=en_us&edition=fundamental","pubTime":"2026-05-22 00:55","pubTimestamp":1779382537,"startTime":"0","endTime":"0","summary":"In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Kailera Therapeutics, Inc., with a price target of $57.00. Werber...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/kailera-therapeutics-inc-klra-receives-a-buy-from-td-cowen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/kailera-therapeutics-inc-klra-receives-a-buy-from-td-cowen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","TD","BK4127","BK4207","BK4585","COWN","KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636418018","title":"Analysts Offer Insights on NA Companies: Arxis, Inc. Class A (ARXS) and Kailera Therapeutics, Inc. (KLRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636418018","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636418018?lang=en_us&edition=fundamental","pubTime":"2026-05-18 00:41","pubTimestamp":1779036113,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Arxis, Inc. Class A (ARXS) and Kailera Therapeutics, Inc. (K...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-arxis-inc-class-a-arxs-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-arxis-inc-class-a-arxs-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARXS","NA","BK4141","BK4187","KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635762235","title":"ADVISORY-Research alert on Kailera Therapeutics withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2635762235","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635762235?lang=en_us&edition=fundamental","pubTime":"2026-05-14 13:25","pubTimestamp":1778736345,"startTime":"0","endTime":"0","summary":"ADVISORY-Research alert on Kailera Therapeutics withdrawnMay 14 (Reuters) - An alert on TD Cowen starting coverage on Kailera Therapeutics Inc KLRA.O is dated and has been withdrawn. There will be no ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nFWN41R08Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635625727","title":"Kailera Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating; Price Target $57","url":"https://stock-news.laohu8.com/highlight/detail?id=2635625727","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635625727?lang=en_us&edition=fundamental","pubTime":"2026-05-14 13:08","pubTimestamp":1778735305,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nFWN41R08Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635751444","title":"This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2635751444","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635751444?lang=en_us&edition=fundamental","pubTime":"2026-05-14 02:43","pubTimestamp":1778697780,"startTime":"0","endTime":"0","summary":"William Blair gives Kailera Therapeutics ($KLRA) an Outperform rating. Learn why analysts see a competitive edge in their GLP-1 assets.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/05/13/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/05/13/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/05/52539772/this-weight-loss-drug-challenger-could-follow-eli-lillys-playbook-analyst","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/05/52539772/this-weight-loss-drug-challenger-could-follow-eli-lillys-playbook-analyst","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["GB00BDT5M118.USD","LU0466842654.USD","LU0943347566.SGD","BK4581","LU2491050071.SGD","LU2237443465.HKD","LU2602419157.SGD","LU2213496289.HKD","LU0708995401.HKD","LU0320765992.SGD","IE00BJLML261.HKD","LU2471134879.HKD","LU0471298777.SGD","LU2361044865.SGD","SG9999015986.USD","IE00BK4W5L77.USD","LU2108987350.USD","LU2264538146.SGD","LU0097036916.USD","IE0004445015.USD","LU1551013425.SGD","IE0001KFT4U8.USD","LU2750360641.GBP","LU1127390331.HKD","SG9999015945.SGD","BK4599","IE00B4JS1V06.HKD","LU2417539215.USD","LU2552382132.HKD","SG9999013999.USD","LU2089284900.SGD","LU1069344957.HKD","LU2089283258.USD","SG9999015952.SGD","SGXZ51526630.SGD","LU0823434583.USD","LU0456855351.SGD","LU2028103732.USD","LU2023250504.SGD","LU0820561818.USD","LU0882574139.USD","LU0058720904.USD","LU0225283273.USD","LU0640476718.USD","IE00BJJMRZ35.SGD","LU2456880835.USD","LU1057294990.SGD","LU2462157665.USD","LU0417517546.SGD","LU1145028129.USD","LU1988902786.USD","LU2491050154.USD","LU0353189680.USD","LU2237443549.SGD","LU0234572021.USD","LU1366192091.USD","LU1868837300.USD","LU1720051017.SGD","IE0005OL40V9.USD","LU1804176565.USD","IE00BKPKM429.USD","LU1868837136.USD","SG9999015978.USD","IE00BJT1NW94.SGD","LU2468319806.SGD","LU0672654240.SGD","IE00B1XK9C88.USD","LU1868836591.USD","LU0006306889.USD","LU1623119135.USD","IE00BJJMRY28.SGD","IE00BFSS8Q28.SGD","LU0889565916.HKD","IE00BKDWB100.SGD","LU1267930730.SGD","LU2089984988.USD","LU2112291526.USD","LU2552382215.SGD","LU2236285917.USD","LU0820562030.AUD","LU0158827781.USD","LLYZ","IE00BWXC8680.SGD","LU0353189763.USD","LU0354030511.USD","LU1720051108.HKD","LU1917777945.USD","SGXZ57979304.SGD","IE0009355771.USD","LU0133085943.USD","BK4007","LU0203201768.USD","LU0683600562.USD","LU2023250330.USD","LLY","IE00BK4W5M84.HKD","LU1023059063.AUD","LU0096364046.USD","LU2063271972.USD","LU2471134952.CNY","LU0320765059.SGD","LU1868836914.USD","LU0158827948.USD","LU0256863811.USD","LLYX","LU2106854487.HKD","LU2361045086.USD","LU2168564149.EUR","LU1064131342.USD","LU1814569148.SGD","LU0964807845.USD","LU0256863902.USD","LU2237443895.HKD","LU0210536198.USD","LU2746668461.USD","SG9999014880.SGD","LU0289739699.SGD","LU2023251221.USD","LU2168563687.JPY","KLRA","SG9999018865.SGD","SG9999001176.SGD","LU0432979614.USD","LU0061475181.USD","ELIS","LU0109394709.USD","IE00B7KXQ091.USD","LU2360106947.USD","LU1989771016.USD","LU0316494557.USD","LU1548497426.USD","LU0203202063.USD","LU2461242641.AUD","LU0354030438.USD","LU0114720955.EUR","LU2471134523.USD","LU2168564495.EUR","LU2168564065.EUR","LU1280957306.USD","LU0323591593.USD","IE00B2B36J28.USD","LU2552382058.USD","ELIL","LU2746668974.SGD","LU2265009873.SGD","SG9999018857.SGD","LU2896262040.SGD","LU0689472784.USD","LU2471134796.USD","LU0786609619.USD","LU1323610961.USD","BK4533","LU2211815571.USD","SG9999001176.USD","BK4585","SGXZ81514606.USD","LU0266013472.USD","IE00BFSS7M15.SGD","IE0004445239.USD","LU1061106388.HKD","BK4588","LU1629891620.HKD","SG9999014906.USD","IE00BN29S564.USD","LU0198837287.USD","LU1093756325.SGD","LU1232071149.USD","BK4516","SGXZ99366536.SGD","LU2087625088.SGD","BK4534","LU2271345857.HKD","SGXZ31699556.SGD","LU0106261372.USD","LU2756315664.SGD","LU2361044949.HKD","IE00BFTCPJ56.SGD","LU1974910355.USD","LU0385154629.USD","LU2756315318.SGD","LU2491049909.HKD","LU2237438978.USD","LU0122379950.USD","LU2750360997.AUD","LU0471298694.HKD","LU1551013342.USD","LU1868836757.USD","LLII","LU2357305700.SGD","LU0109391861.USD","LU0820561909.HKD","LU0823434740.USD","LU0823416689.USD","LU2168564222.USD","LU1093756168.USD","LU0882574055.USD","LU1712237335.SGD","IE0002141913.USD","LU0787776722.HKD","LU2237443622.USD","IE00BJJMRX11.SGD","LU2324357040.USD","LU2237443382.USD","LU1291159041.SGD","IE00B1BXHZ80.USD","LU0079474960.USD","IE00B775H168.HKD","LU0094547139.USD","IE00B4R5TH58.HKD","SG9999017495.SGD","LU1035775433.USD","SG9999014898.SGD","SG9999014914.USD","LU1983299246.USD","LU2111349929.HKD","LU2237443978.SGD","LU0238689110.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635789072","title":"Kailera presents Phase 1 ribupatide injection data supporting global Phase 3 KaiNETIC program at ADA","url":"https://stock-news.laohu8.com/highlight/detail?id=2635789072","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635789072?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:31","pubTimestamp":1778671895,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics announced 2 clinical data poster presentations on ribupatide, its dual GLP-1/GIP agonist program for obesity and overweight, scheduled for June 5-8, 2026 at American Diabetes Association 86th Scientific Sessions in New Orleans.Results have not yet been presented; Kailera plans to show Phase 1 bridging study data for injectable ribupatide on June 8.Study readout supported initiation of Kailera ongoing global Phase 3 KaiNETIC clinical program, positioning injectable ribupatide as lead near-term value driver in its obesity pipeline.Partner Hengrui Pharma will also present Phase 2 results for oral ribupatide on June 7, expanding optionality across oral and injectable formats without disclosing outcomes in this announcement.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL3vdWDt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014013.SGD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","NDAQ","IE00BN0W2T93.GBP","BK4139","IE00BGHQF748.EUR","BK4588","BK4112","KLRA","SG9999014005.SGD","LU0314104364.USD","BK4585","LU2210150020.SGD","IE00BN0W2W23.USD","SG9999014039.USD","IE00BKPKM429.USD","SG9999014021.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635878901","title":"Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions","url":"https://stock-news.laohu8.com/highlight/detail?id=2635878901","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635878901?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:30","pubTimestamp":1778671800,"startTime":"0","endTime":"0","summary":"Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and ove","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293890/0/en/Hengrui-Pharma-and-Kailera-Therapeutics-Announce-Clinical-Data-Presentations-at-the-American-Diabetes-Association-86th-Scientific-Sessions.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA","BK4139","BK4117","BK4107","AFG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635724525","title":"Kailera Therapeutics initiated with an Outperform at Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2635724525","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635724525?lang=en_us&edition=fundamental","pubTime":"2026-05-12 23:50","pubTimestamp":1778601012,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Umer Raffat initiated coverage of Kailera Therapeutics (KLRA) with an Outperform rating and no price target Kailera is “making...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-initiated-with-an-outperform-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-initiated-with-an-outperform-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634245888","title":"Kailera Therapeutics Initiated at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2634245888","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634245888?lang=en_us&edition=fundamental","pubTime":"2026-05-12 23:36","pubTimestamp":1778600160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KLRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 11:36 ET (15:36 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kailera.com","stockEarnings":[{"period":"1week","weight":0.0184},{"period":"1month","weight":0.0143},{"period":"3month","weight":0.2437},{"period":"ytd","weight":0.2437}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Kailera Therapeutics","nameEN":"Kailera Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kailera Therapeutics(KLRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kailera Therapeutics(KLRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kailera Therapeutics,KLRA,Kailera Therapeutics股票,Kailera Therapeutics股票老虎,Kailera Therapeutics股票老虎国际,Kailera Therapeutics行情,Kailera Therapeutics股票行情,Kailera Therapeutics股价,Kailera Therapeutics股市,Kailera Therapeutics股票价格,Kailera Therapeutics股票交易,Kailera Therapeutics股票购买,Kailera Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kailera Therapeutics(KLRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kailera Therapeutics(KLRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}